Subject Index

A
acetylation, hepatic, alteration in uraemia, 433
acid excretion, in severe rejection, 326
acidification, urinary, in renal allograft, 277
acidosis
  hydrochloric-acid induced, and urea excretion, 411
  renal ammonium excretion and, 411
ACTH
  pituitary, and plasma aldosterone, 268
  release, plasma cortisol and, 268
aldosterone, plasma
  circadian rhythm of, in allograft recipients, 268
  pituitary ACTH, influence of, on, 268
allergy, to drugs, hypersensitivity nephritis from, 526
allograft, see renal transplant
amino acids, renal failure, chronic, changes in, 192
ammonium excretion and metabolic acidosis, 411
ampicillin, allergy to, 527
anaemia
  in chronic renal failure and dialysis
    patients, histidine and iron supplementation, 391
  uraemic, and porphyric metabolism, 383
annual report, EDTA 1973-74, 561
antibodies, anti-donor, transplant, after, 343
antiglomerular basement membrane antibodies, after transplant, 343
antihypertensive agents, see thrombolytic agents
antihypertensive therapy, protection for haemodialysis unit team with, 237
antilymphocyte globulin, 301
  concentration, to indicate transplant rejection, 320
aspergillosis, transplantation, 303
ATPase enzyme, changes of, in kidney preservation, 294
audiometry
  in chronic renal failure, 203
  haemodialysis, effects on, 203
Australia antigen immunoglobulin, protection for haemodialysis unit team, with, 237
autoregulation, glomerular haemodynamics and, 77
azathioprine, 301, 492
  in treatment of acute rejection, 355

B
bacterial infection after renal transplantation, 300
blood
  access in haemodialysis, 69
  flow rate in short time dialysis, 153
  pressures, short dialysis schedules, 114
  transfusion,
    graft survival and, 1973, 22, 24
    quality of blood, 1973, 52
urea in short time personalised dialysis, 146
bone disease, renal, see renal osteodystrophy
bone lesions
  in early renal failure, 443
  histological, chronic renal failure, changes in, 192
Bratton-Marshall reaction, serum levels of sulphamethoxazole, to show, 406
BUN in short time personalised dialysis, 146

C
cadaver kidney transplantation, survival after, 1973, 14, 19
calcium
acute intravenous infusion in chronic renal failure, 465
homeostasis, transplantation in reversing derangement after haemodialysis, 261
in dialysate regeneration, 173
supplements, in renal osteodystrophy, 473

cellular immunity
in urinary acidification defect, 281
renal transplant, after, 343

children
centres for dialysis and transplantation, 1973, 3, 4
dialysis for very young, 247
patients in dialysis and transplantation centres, 1973, 3, 4
rehabilitation in, 1973, 45
renal disease, 1973, 8, 9
renal transplantation in very young, 247
retransplantation in, 1973, 6, 7
survival after dialysis or transplantation, 1973, 13
transplantation for very young, 247
treatment for very young, 1973, 11
chlorpromazine, pre-treatment of donor kidneys with, 287
chronic consumption coagulopathy in oxalosis, 360
circadian rhythm, of plasma renin activity and plasma aldosterone in allograft recipients, 268

clearance
of methylguanidine, 105
of parathyroid hormone, 457
ultrafiltration system in creatinine, 160
clonidine, in association with propranolol, 223

closed-batch system, peripheral neuropathy and, 214

coil regeneration system in daily haemodialysis, 128

complement
C₄, in drug allergy, 526
deposition
in glomerular diseases, 515
in lupus glomerulonephritis, 506
congenital nephrotic syndrome, transplantation for young children with, 247
corticosteroids, see steroids
cortisol, plasma, ACTH release and, 275
creatinine
 clearance, ultrafiltration system, in, 160
levels,
in short time personalised dialysis, 146
rehabilitation and, 1973, 44, 45
crescent formation, significance in glomerulonephritis, 522
cryoglobulinaemia glomerulonephritis, complement deposition in, 515
cyclophosphamide to treat proliferative glomerulonephritis, 491
cytomegalovirus infections after renal transplantation, 300
cytotoxic antibodies, graft survival and, 1973, 22, 24

d

defauness
haemodialysis, effects of, on, 203
in chronic renal failure, 203
dead
causes,
dialysis patients, 1973, 16, 21
transplantation, after, 1973, 21
electrocardiography during haemodialysis, 210
delta-aminovaleric acid dehydrogenase in anaemia due to iron deficiency, 388
lead poisoning, 388
in reticulocytes from uraemic patients, 383
diagnostic marker of rejection, proteinuria as, after transplantation, 333
dialysate
 glucose content, effect of, 373
recirculating system, 173
ten litre, 180
two square metre hollow fibre kidney, 153
dialysers
ASAHJumbo, 153
coils, re-use of, 129
Dasco SP75, 374
disposable, cost effectiveness of, 551
Gambro, 147
double, trial of, 121
Gambro-Lundia, 384
Hollow Fibre kidney, 153
Kii, 68, 147, 374
membrane, permeability of, middle molecule retention and, 219
portable, cost effectiveness of, 550
dialysis kit, 69
RP6, neuropathy and, 214
re-use of, machine for, 187
two square metre Hollow Fibre kidney, 153
types used, 1973, 46, 47
UF2, 374
UF100, 374

566
dialysis
centres, number of patients, 1973, 3, 5
in Europe 1973, 3, 4
children, very young, 253
chronic, treatment of resistant arterial
hypertension, 222
death, causes of, on, 1973, 16, 21
duration of, 46, 539
and metabolism of carbohydrates and
lipids, 374
fluid, see dialysate
forecast for, 1973 report, 55
frequency and duration of, 46
haemo-, see haemodialysis
hepatic acetylation, and, 46
hepatitis, 1973, and, 50
histidine supplementation for patients
on, 391
home, see home dialysis
hospital centres,
patient load, 1973, 5
compared with home and limited
care dialysis, 545
survival on, 1973, 15
iron supplementation for patients on, 391
limited care dialysis, compared with
home and hospital dialysis, 545
machine for dialyser re-use, 187
methylguanidine, removal of, by 105
middle molecules and, 417
patients,
age distribution, 1973, 10
number related to population, 1973, 53
sex distribution, 1973, 10
peritoneal, home, 70
permanent home installations,
eliminating, 550
polyacrylonitrile, peripheral neuropathy
and, 214
portable equipment for, 550
pregnancy on, 1973, 39
progress, discussion of, 537
rehabilitation, see rehabilitation
schedule, short, 112
short time,
glucose, effect of; 377
mathematical single-pool model for, 136
personalised, 146
re-appraisal of, 539
with two square metre Hollow Fibre
kidney, 153
single needle, appraisal, 167
starting time for, early, 192
survival,
after seven years, 256
of more than eight years on, 1973, 5, 7
on, 1973, 11
dialysis—cont.
time of day for, 1973, 46
transplantation, survival, comparison
with, 256
diet, middle molecules and, 417
diurnal rhythm of plasma renin activity and
plasma aldosterone in allograft
recipients, 268
DNA synthesis
effect of haemodialysis on, 367
inhibition by guanidine compounds in
uraemia, 427
dog kidneys
preservation, changes of renal ATPase
in, 294
to study parathyroid hormone
metabolism, 457
donor kidneys, chlorpromazine pre-treat-
ment of, ischaemic, 287
donors, kidneys, nature of, 1973, 6
drug allergy, hypersensitivity nephritis from,
526
drugs
immuno-suppressive,
antilymphocyte globulin, 301
aza-thioprine, 301
prednisolone, 301
to treat proliferative glomerulo-
nephritis, 491
E
electrical safety, kidney machines, 210
electrocution, death due to, during
haemodialysis, 210
emboli, infected, after renal transplantation,
304
enzymes, ATPase, changes of, in kidney
preservation, 294
erthropoiesis
changes in uraemia, 192
effect of erythropoietin on, 398
renal failure, chronic, changes in, 192
erthropoietin in renal insufficiency, 398
extracapillary proliferation in glomerular
disease, significance of, 522
F
fibrin degradation products
haematuria and, 313
urinary excretion of, in acute renal graft
rejection, 311
fistula
flow, single needle dialysis, 168
replacement of shunt by, 69
single-needle, in ‘daily’ haemodialysis,
130
focal
glomerulosclerosis, complement
deposition in, 515
proliferative glomerulonephritis,
complement deposition in, 515
forecast
calculation, 1973, 61
for dialysis and transplantation, 1973,
55
fungus infections after renal transplantation,
300

G
gastro-intestinal symptoms in uraemia,
middle molecular peaks, 417
gentamycin, NAG excretion and, 314
glomerular
diseases, complement deposition in, 515
haemodynamics and autoregulation, 77
hydrostatic pressure, 77
glomerulonephritis
acute, complement deposition in, 515
biopsy data, significance of, 522
classification of, 89
histological, 1973, 9, 10
cryoglobulinaemia, complement
deposition in, 515
focal proliferative, complement
deposition in, 515
lupus, see lupus nephritis
proliferative, cyclophosphamide to treat,
491
transplantation for young children with,
247
glomerulonephropathies, classification of,
89
glomerulosclerosis, focal, complement
deposition in, 515
glomerulus, artificial, 153

H
haematocrit, short dialysis schedules, 114
haematuria, NAG and FDP excretion and,
313
haemodialysis
audiometric studies before and after,
203
brief ‘daily’, trial of, 128
‘daily’, trial of, 128
DNA synthesis, effect of, 367
double dialysers, using, 121
electrocution during, 210
hearing, effect on, of, 203
immune response, effect on, 367
mathematical single-pool model for, 136
microampere electrocution during, 210
short time, mathematical model for, 136
haemolysis, ultrafiltration system in, 158
haemoptysis in bacterial pulmonary
infections, 301
hearing impairment
haemodialysis, effects of, on, 203
in chronic renal failure, 203
heparin to treat acute anuric lupus nephritis,
500
hepatic acetylation, alteration of in uraemia,
433
hepatitis
haemodialysis unit team, immuno-
globulin protection for, 237
incidence, 1973, 49
histidine supplements in dialysis and
pre-dialysis patients, 391
histological classification of glomerulo-
nephritis, 1973, 9, 10
HL-A matching in transplantation, 1973, 24
home dialysis
compared with hospital and limited care
dialysis, 545
future developments, 73
improvements possible, 555
in 1973, 52
peritoneal, 70
present situation, 555
problems and failures, 72
quality of life and, 72
rehabilitation and, 72
responsibility for, 69
single-needle dialysis, appraisal of, 167
staffing for, 73
survival rates, 71
survival rates, 1973, 19
ten years’ review, 68
training for, 69
homograft, see renal transplanthumoral
immunity

568
homograft—cont.
  in urinary acidification defect, 280
  renal transplant, after, 343
hydrogen ion excretion, after renal transplant, 277
hydroxyproline
  concentration, plasma, after acute intravenous infusion of calcium in chronic renal failure, 465
effect of transplantation on, 359
hyperoxaluria, primary, terminal renal failure due to, 359
hyperparathyroidism
  in chronic renal disease, 457
  secondary, effect of transplant, 261
  in mild renal failure, 451
  renal osteodystrophy and, 481
  transplantation after haemodialysis, effect on, 261
hypersensitivity nephritis, drug-induced, 526
hypertension
  chronic dialysis patients, treatment, 222
  pulmonary artery, minoxidil and, 234
  resistant arterial, propranolol for, 222 severe,
in chronic renal failure, 229
  and minoxidil, 229
  short dialysis schedules, 114
hypocalcaemia and parathyroid hormone in mild renal failure, 451
hypoplastic-dysplastic kidneys, transplantation for young children with, 247

K
kidney
donors, 1973, 6
failure, see renal failure
function, deficient metabolic, peripheral neuropathy and, 214
preservation, changes of renal ATPase enzymes in, 294
role in parathyroid hormone degradation, 457
kidneys, donor, chlorpromazine pre-treatment of, 287

L
liver, role in uraemia, 433
lung abscesses, 304
lupus erythematosus
  systemic, 506
  lupus nephritis, treatment for, 500
lupus nephritis
  acute anuric reversible, 500
  complement deposition in, 515
  immunoglobulin and complement deposits in, 506
lymphocytes
  in-vitro reactivity, guanidine compounds and, 427
  T-lymphocytes, rosette inhibition test to determine, 320

M
magnesium, supplements in renal osteodystrophy, 473
mathematical model, single-pool, for short time haemodialysis, 136
membranoproliferative glomerulonephritis, complement deposition in, 515
mental confusion in uraemia, middle molecular peaks, 417
methicillin, allergy to, 527
methionine sulphoximine and acidosis, 411
methylguanidine
dialysis behaviour of, 105
removal by dialysis of, 105
see also guanidine compounds
uraemic toxin, as, 105
middle molecule hypothesis, 146
middle molecules and dialysis, 417
  and diet, 417
  peripheral neuropathy and, 214
  short dialysis schedules, 113
  short time personalised dialysis, levels in, 146
ultrafiltration for, in uraemia, 158
middle molecules—cont.
in uraemia, detection and quantification, 417
in uraemia, ultrafiltration for, 158
minoxidil
for severe hypertension in chronic renal failure, 229
hirsutism and, 235
pulmonary artery hypertension and, 234
mixed lymphocyte culture in renal transplant patients, 344
molecular weight, importance in dialysis, 109
motor nerve conduction velocity, 50, 194
see also neuropathy, peripheral
short dialysis schedules, 113

N
N-acetyl-D-glucosaminidase
gentamycin and, 314
haematuria and, 313
urinary excretion of, in acute renal graft rejection, 311
nephrectomy
reasons for, 1973, 41
total, 1973, 40
total, minoxidil for hypertension in place of, 229
nephritis
hypersensitivity nephritis, drug induced, 526
see also glomerulonephritis, and lupus nephritis
nephroblastoma, transplantation for young children with, 247
nephrotic syndrome, congenital, transplantation for young children with, 247
nerve conduction velocity, see motor nerve conduction velocity
neuropathy, peripheral
renal failure, chronic, changes in, 192
see also motor nerve conduction velocity uraemia, changes in, 192
uremic, clinico-chemical correlations, 214
neutron activation analysis of hand, to measure skeletal demineralisation, 473
nitrogen balance, dialysate regeneration, ten litre supply system, 180

O
older patients accepted for therapy, 1973, 11
open lung biopsy, 300
osteitis fibrosa after renal transplantation, 481
osteodystrophy, renal, see renal osteodystrophy
osteomalacia after renal transplantation, 481
see also renal osteodystrophy
oxalosis, terminal renal failure due to, 359

P
paediatrics, see children
parathyroid hormone
action in mild renal failure, 451
extra-renal degradation in uraemia, 457
kidney’s role in degradation, 457
metabolism, in chronic renal disease, 457
overactivity, skeletal, in early renal failure, 443
parathyroid suppressibility in renal osteodystrophy, 465
patients in dialysis and transplantation centres, 1973, 3, 5, 10, 11, 53, 54
pericarditis
in uraemia, middle molecular peaks in, 417
short dialysis schedules, 116
peripheral neuropathy, see neuropathy, peripheral
peritoneal dialysis, home, 70
phosphate
depletion, effect on osteomalacia after transplantation following haemodialysis, 265
level, in short time dialysis, 151
pituitary ACTH, plasma aldosterone, circadian rhythm of, influence on, 274
plasma aldosterone, see aldosterone, plasma
cortisol, ACTH release and, 275
plasma hydroxyproline, see hydroxyproline
plasma renin activity
propranolol and, 223, 226
renal innervation and, 268
plasma-solute depletion, peripheral neuropathy and, 214
pleural biopsy, 300
pleural effusion in bacterial pulmonary infections, 301
pneumococcus, 304
Pneumocystis Carinii infections after renal transplantation, 300
polycystic kidneys, transplantation for young children with, 247
polyneuritis, see neuropathy, peripheral
population, number of patients related to, 1973, 53
porphyrin metabolism in uraemic patients, 383
porphobilinogen desaminase in reticuloctyes
from uraemic patients, 383
prednisolone, 301
to treat acute rejection, 351
pregnancy on dialysis or transplantation, 1973, 39
preservation, kidney, changes of renal
ATPase enzyme in, 294
pressure
blood, short dialysis schedules, 114
glomerular, 89
properdin in lupus glomerulonephritis, 506
propranolol
and plasma renin activity, 223, 226
to treat resistant arterial hypertension in
chronic dialysis patients, 222
with minoxidil, 229
protein
metabolism, in chronic renal failure and
dialysis patients, histidine and
iron supplementation in, 391
turnover, renal failure, chronic, changes in, 192
proteinuria, as diagnostic marker of
rejection after transplantation, 333
protozoan infections after renal transplanta-
tion, 300
pulmonary infections after renal transplanta-
tion, 300
Q
quality of life, see rehabilitation
R
recirculation
of dialysate, 173
ten litre supply system, 180
single needle dialysis, 167
regeneration, see recirculation
registry, statistics from, 1973, 3
rehabilitation
dialysis and transplantation, 256
‘effective’ or ‘apparent’, 192
in children, 1973, 45, 46
in home dialysis, 72
rejection, see renal transplant, rejection
renal arterioles in drug allergy, 526
renal disease
chronic, see renal failure, chronic
experimental, parathyroid hormone
metabolism in, 457
in children, 1973, 8, 9
primary, 1973, 7, 8
rarer forms, 1973, 9
renal failure
acute, proteinuria connected with, 333
anuric, and lupus erythematosus,
treatment for, 500
chronic,
acute intravenous infusion of
calcium, 465
audiometry in, haemodialysis, effect on, 203
changes, dialysis, effects on, 192
distribution, 192
hearing, haemodialysis, effects on, 203
histidine supplementation for, 391
iron supplementation for, 391
severe hypertension in, 229
see also uraemia
early,
bone lesions in, 443
see also renal failure, mild
erythropoietin in, 398
mild,
parathyroid hormone homeostasis
and action in, 451
see also renal failure, early
terminal, due to oxalosis, 359
renal innervation, circadian rhythm of plasma
renin activity and, 268
renal osteodystrophy
assessment following renal transplanta-
tion, 481
effect of transplantation after
haemodialysis on, 261
1α-hydroxylcholecalciferol as treatment for, 473
in early renal failure, 443
in short dialysis schedules, 117
investigation and treatment, 473
osteomalacia, after renal transplantation,
481
parathyroid suppressibility in, 465
see also bone lesions
serum biochemistry as indicator, 446
renal transplant
acceptance, reasons for, 343
donors, 1973, 6, 7
graft failure, causes of, 1973, 22, 23
graft survival, in relation to tissue typing,
cytotoxic antibodies and blood
transfusion prior to grafting, 1973, 22
recipients,
age distribution, 1973, 10
circadian rhythm of plasma renin
activity and plasma aldo-
sterone in, 268
rejection,
acute, minimising risks of treating, 351
renal transplantation—cont.

rejection—cont.

acute, NAG and FDP, urinary excretion of, in, 311
acute, test for early detection of, 326
antilymphocyte globulin, to indicate, 320
and hydrogen ion excretion, 277
NAG and FDP, urinary excretion of, in, 311
proteinuria and episodes of, 333
rosette inhibition test to diagnose, 320
severe, minimising risks of treating, 351
severe, NAG and FDP, urinary excretion of, in, 311
severe, test for early detection of, 326
and urinary acidification, 277
renal transplantation
acidification, urinary, after, 277
after pulmonary infections, 300
and dialysis, survival, comparison of, 256
assessment of renal osteodystrophy following, 481
cadaver kidney, survival after, 1973, 14, 20
centres
in Europe, 1973, 3, 4
number of patients in 1973, 3, 5
children, retransplantation, 1973, 6, 7
death, causes of, after, 1973, 21
effect of secondary hyperparathyroidism, 261
effects on calcium homeostasis, 261
forecast, 1973, 55
graft
failure, causes of, 1973, 22, 23
survival, in relation to tissue typing, cytotoxic antibodies and blood transfusion prior to grafting, 1973, 22
hepatitis and, 1973, 24
HL-A matching, 1973, 24
in siblings and parent-donor grafts, tissue typing, 1973, 28
in very young children, 247
number of patients related to population, 1973, 53
pregnancy after, 1973, 39
retransplantation in children, 1973, 6, 7
survival after, 1973, 11
failure of first graft, 1973, 7, 8
seven years, 256
renal transplantation—cont.
survival of more than eight years, 1973, 5, 7
renal tubular acidosis, distal, 281
rheumatoid purpura glomerulonephritis, complement deposition in, 515
rifampicin, allergy to, 527
rosette inhibition test in early diagnosis of renal allograft rejection, 320

S
salmonella, 304
sepsis, see infections
serum anti-C3 in drug allergy, 526
serum transferrin, histidine supplementation and, 391
shock in bacterial pulmonary infections, 301
short dialysis schedules, 112
shunt, fistula as replacement for, 69
single needle dialysis, appraisal of, 167
skeletal demineralisation, measurement by neutron activation analysis, 473
skeletal lesions in early renal failure, 443
small molecules, short time personalised dialysis, high levels in, 146
sodium diatrizoate, allergy to, 530
staff, hepatitis in, 1973, 49
staphylococci, 304
statistical report, 1973, 3
computer programme for, 63
steroid therapy, in acute rejection, minimising risks, 355
steroids, to treat acute anuric lupus nephritis, 500
sulpha drugs, allergy to, 530
sulphadimidine, rate of acetylation of, 433
sulphamethoxazole, conjugated, delayed excretion in uraemia, 405
survival
after failure of first graft, 1973, 7, 8
after transplantation, 1973, 11
by age, 1973, 13, 16
cadaver kidney transplantation, after, 1973, 14
more than eight years on dialysis or after transplantation, 1973, 5, 7
on dialysis, seven year follow-up, 256
on dialysis, 1973, 11
rates, calculation, 1973, 60
transplantation, after, seven year follow-up, 256
young children after transplantation, 247
systemic lupus erythematosus, see lupus erythematosus
thymidine incorporation in uraemia, 427

tissue typing
  graft survival and, 1973, 22, 24
  in sibling and parent-donor grafts, 1973, 28

T-lymphocytes, rosette inhibition test to determine, 320

transplant, transplantation, see renal transplant, renal transplantation

triglycerides, renal failure, chronic, changes in, 192

U

ultrafiltration
  method, extracorporeal, 154
  rates, single needle dialysis, 171
  system, middle molecules in uraemia, for, 158

uriaemia
  delayed excretion of conjugated sulphamethoxazole in, 405
diazotable aromatic amines in, 409
erythropoietin in, 398
extrarenal degradation of parathyroid hormone, and, 457
hepatic acetylation, alteration of, in, 433
histidine supplementation in, 391
inhibition of DNA synthesis by guanidine compounds in, 427

uraemia—cont.
  iron supplementation in, 391
  liver, compensatory role of, in, 433
  middle molecules in,
    detection and quantification, 417
    ultrafiltration for, 158
  porphyrin metabolism in, 383
  see also renal failure, chronic
  serum, substances in, detection of, 405
  ultrafiltration for middle molecules in, 158

uraemic changes
  dialysis, effects on, 192
  distribution, 192
uraemic polyneuritis, see neuropathy, peripheral
uraemic toxic, methylguanidine as, 105
urea excretion, urinary, production of middle molecules, connection with, 214
urease, dialysate, recirculation in, 174
urinary acidification in renal allograft, 277
excretion of NAG and FDP in acute renal grant rejection, 311

V

virus infections after renal transplantation, 300